These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2501273)

  • 1. Fleroxacin concentrations in myometrium, ovary and fallopian tube.
    Portmann R; Hansz C; Stiglmayer R; Weidekamm E
    J Antimicrob Chemother; 1989 Apr; 23(4):662-4. PubMed ID: 2501273
    [No Abstract]   [Full Text] [Related]  

  • 2. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of pelvic tissue concentrations after oral administration of enoxacin.
    Bates SA; Elder MG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():79-85. PubMed ID: 3162905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues.
    Gerstner GJ; Dalhoff A; Weuta H
    Infection; 1988; 16 Suppl 1():S24-8. PubMed ID: 3372029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
    Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
    Weidekamm E; Stöckel K; Dell D
    Chemioterapia; 1987 Jun; 6(2 Suppl):307-8. PubMed ID: 3151346
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparison of the penetration of two quinolones into intra-abdominal abscess.
    Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
    Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of ciprofloxacin and fleroxacin into biliary tract.
    Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
    Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
    Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
    Wise R; Kirkpatrick B; Ashby J; Griggs DJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):161-3. PubMed ID: 3105446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
    Baba S; Mori Y; Maruo T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():195-7. PubMed ID: 3144538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetration of ciprofloxacin into female pelvic tissues.
    Segev S; Rubinstein E; Shick J; Rabinovitch O; Dolitsky M
    Eur J Clin Microbiol; 1986 Apr; 5(2):207-9. PubMed ID: 2941283
    [No Abstract]   [Full Text] [Related]  

  • 19. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.
    Jynge P; Skjetne T; Gribbestad I; Kleinbloesem CH; Hoogkamer HF; Antonsen O; Krane J; Bakøy OE; Furuheim KM; Nilsen OG
    Clin Pharmacol Ther; 1990 Nov; 48(5):481-9. PubMed ID: 2121409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.